Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Combined with Trastuzumab and Abraxane in HER2-positive MBC with Brain Metastases
NCT04639271Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, brain metastases, sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancerbrain metastases
Beyond the preview
Go deeper on NCT04639271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639271.